knowledge -WSS

knowledge

author：knowledge 2025-10-04 11:35:35 - browse：4892

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Microbiome research is starting to find links to chronic diseases

WSS

Congress considering partial increase for doctor pay in Medicare

Hearing on Medicare drug price negotiation gets unusually heated

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Why Eli Lilly’s earnings didn’t quite live up to the hype

CDC's new outbreak response network to include Northeastern

focus

knowledge

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Microbiome research is starting to find links to chronic diseases

Cancer drug shortages should be causing more outrage

Changes to biosimilar regulatory framework must prioritize patients

Dobbs anniversary: the lost opportunity of abortion as health care

AMAs digital advisors table RPM coding reform proposal, again

How one medical school became remarkably diverse

Thermo Fisher plant for manufacturing gene therapies to expand

What does generative AI mean for health care? We asked experts

Thermo Fisher plant for manufacturing gene therapies to expand

hotspot

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Having children helps parents live longer, especially after age 80

Biotech stock slump in 2023: awaiting the turnaround

Readout LOUD podcast: possible new ALS drug, artificial wombs

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Readout LOUD podcast: possible new ALS drug, artificial wombs

leisure time

explore

focus

explore